KOSDAQBiotech & Pharma206640

Boditech Med

₩9,600▼ 1.54%2026-11-18 close
Market Cap
₩206.5B
Turnover
₩200M
Volume
30K
Shares out.
21.5M
PER
10.2×
PBR
0.8×
EPS
₩939
Dividend Yield
1.57%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩150 per share · Prices as of the 2026-11-18 close

01

Report overview

Operating profit recovers while net profit lags

Boditech Med's operating profit rose for three straight quarters from Q1 to Q3 2026, while profit attributable to controlling shareholders has fallen for two quarters since its Q1 2026 peak, leaving the earnings direction mixed.

  1. 1

    Revenue reached KRW 162.1 billion in 2025, up 17.3% year on year and the largest year of 2022–2025; the company described it as a record high.

  2. 2

    Profit attributable to controlling shareholders fell 13.1% to KRW 23.7 billion in 2025, so revenue growth did not carry through to that profit line.

  3. 3

    Q3 2026 operating profit rose 35.2% year on year to KRW 8.93 billion, and cartridge finished-product sales rose 24% to KRW 38 billion in the same quarter, based on the November 6, 2026 preliminary release.

  4. 4

    Operating margin eased to 17.9% in 2025 from 18.9% in 2024, which the company attributed to expanded investment in headcount and R&D.

  5. 5

    European sales and domestic in-hospital testing demand led growth in 2026.

02

Business structure

Boditech Med is an in-vitro diagnostics company that runs point-of-care tests in clinics and hospitals, selling analyzers together with the cartridges consumed per test.

Its core platforms are the Ichroma and AFIAS series, and cumulative new installations of these two platforms reached 9,493 units in the first three quarters of 2026, up 26.7% year on year.

Because cartridges are repurchased as installed bases grow, cartridge finished-product sales of KRW 38 billion in Q3 2026, up 24% year on year, equaled roughly 79% of that quarter's revenue.

Immunodiagnostics remains the core, and the company is widening its scope into biochemistry, blood analysis and animal diagnostics. By region in 2025, the Middle East and North Africa (MENA) was the largest at 26% of sales, Europe grew 22%, and Latin America rose more than 40%.

Domestic sales topped KRW 12 billion a year. In Q2 2026, European sales rose 67% to KRW 14.1 billion, lifting the region to about 30% of revenue. The company said in a 2024 interview that overseas sales exceed 90% of the total.

On competition, Chinese in-vitro diagnostics companies have grown fast, and the CEO said most domestic hospital analyzers had been taken by China's Mindray. The company has said it faces difficulties in China due to copycat products and political factors.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩39.9B₩6.6B16.5%
2025Q4₩41.6B₩5.1B12.2%
2026Q1₩42.8B₩6.8B15.9%
2026Q2₩50.4B₩8.2B16.3%
2026Q3₩48B₩8.9B18.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩118.1B₩24.7B₩25.3B20.9%15.5%11.9%
2023₩134.2B₩28.5B₩26.7B21.2%14.3%15.4%
2024₩138.2B₩26.2B₩27.2B18.9%12.9%14.2%
2025₩162.1B₩28.9B₩23.7B17.9%10.2%15.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Revenue rose from KRW 118.1 billion in 2022 to KRW 134.2 billion in 2023 (up 13.7%), KRW 138.2 billion in 2024 (up 2.9%) and KRW 162.1 billion in 2025 (up 17.3%), and it has grown three years in a row from 2023 through 2025. 2025 was the largest year of 2022–2025.

Operating profit went from KRW 24.7 billion in 2022 to KRW 28.5 billion in 2023 (up 15.4%), fell to KRW 26.2 billion in 2024 (down 8.2%), and recovered to KRW 28.9 billion in 2025 (up 10.7%).

Operating margin declined from 20.9% in 2022 and 21.2% in 2023 to 18.9% in 2024 and 17.9% in 2025, so revenue grew faster than profit as the margin narrowed. The company attributed the 2025 margin decline to larger upfront investment for future growth.

Headcount rose from 321 at the end of 2019 to 618 at the end of 2025, and research staff increased from 88 to 170. Profit attributable to controlling shareholders rose from KRW 25.3 billion in 2022 to KRW 26.7 billion in 2023 and KRW 27.2 billion in 2024, then fell 13.1% to KRW 23.7 billion in 2025.

Net profit including non-controlling interests was KRW 23.9 billion in 2025. Operating cash flow was KRW 23.1 billion in 2022, KRW 34.3 billion in 2023, KRW 24.9 billion in 2024 and KRW 22.1 billion in 2025.

Quarterly operating profit bottomed at KRW 5.05 billion in Q4 2025, down 23.5% from Q3 2025, then rose to KRW 6.8 billion in Q1 2026, KRW 8.24 billion in Q2 and KRW 8.93 billion in Q3, three consecutive quarterly increases.

Profit attributable to controlling shareholders peaked at KRW 9.59 billion in Q1 2026 and then fell to KRW 7.3 billion in Q2 and KRW 2.08 billion in Q3, two consecutive declines. The last four quarters total KRW 20.2 billion.

The reasons for the sharp Q1 swing will be found in non-operating items and tax lines of the next annual report.

05

Industry analysis

A 2024 interview report cited estimates by Frost & Sullivan putting the global in-vitro diagnostics market at about USD 118.9 billion in 2025, with immunodiagnostics at roughly USD 35.9 billion, the largest segment. Boditech Med's focus on immunodiagnostics sits inside that market structure.

In Korea, clinics have been moving to run tests in-house ahead of the revision of the specimen testing outsourcing rules scheduled to take effect in December 2026. The company said domestic sales rose 44% in Q2 2026 and 47% in the first half.

In the cycle, many domestic diagnostics companies saw sales decline after the COVID-19 testing boom, and a 2024 interview report described Boditech Med as nearly the only domestic diagnostics company still growing after the endemic shift.

The company said 2025 revenue exceeded the KRW 157.7 billion posted in 2021, its previous peak.

Competitively, the CEO said Chinese in-vitro diagnostics companies are expanding abroad on the back of government-backed domestic markets, and the company has said it aims at products China has not developed and markets it has not entered.

In regional supply, geopolitical uncertainty in the Middle East and North Africa is a variable: sales there fell 6.2% in Q2 2026 and then rose 10% to KRW 11.7 billion in Q3. The company said Czech sales more than quintupled in the first half of 2026 and German sales rose 62%.

06

Outlook

In a July 2026 report, the company said it aims to grow annual revenue by 15% a year from 2026 and reach KRW 300 billion by 2030. At the same time it expected first-half 2026 revenue to rise 10% to 20% year on year. Actual first-half revenue reached KRW 93.3 billion, up 15.7%, within that range.

A 2024 interview had set KRW 500 billion as the 2030 goal, a different marker from the current target. A 2023 interview had set KRW 200 billion for 2025, and 2025 revenue came in at KRW 162.1 billion.

On new businesses, the company said in its Q3 2026 release that it will expand market entry for new diagnostic platforms.

Cumulative installations of its main platforms reached 9,493 units in the first three quarters of 2026, above the 9,280 units installed in all of 2025, and the company said this broadens the base for cartridge sales.

In Korea, the key question is whether in-hospital testing demand holds after the December 2026 outsourcing rule revision takes effect. Regionally, Middle East and North Africa geopolitics runs against Europe's expansion. The company said its Q3 2026 release showed the margin recovery continuing.

The next annual report for 2026 is the next checkpoint for how annual revenue growth and operating margin compare with 17.9% in 2025.

07

Valuation

PER
10.2×
PBR
0.8×
ROE
8.7%
EPS
₩939
BPS
₩11,285
Dividend per share
₩150

The price-to-book ratio is below 1x, which means market capitalization is below the book value of equity attributable to controlling shareholders.

At the end of 2025, total equity was KRW 244.2 billion, of which KRW 231.3 billion belonged to controlling shareholders, and total liabilities were KRW 37.5 billion, a debt-to-equity ratio of 15.3%, so borrowing is light relative to equity. The company has paid cash dividends for ten consecutive years since 2016.

Its board decided in the 2025 results period to cancel 1,438,250 treasury shares, about 6.2% of listed shares outstanding. The treasury stake had earlier risen from 1.96% in September 2020 to 6.98% in February 2026.

On earnings, profit attributable to controlling shareholders over the last four quarters totals KRW 20.2 billion, and quarterly swings are large enough that earnings-based multiples can look quite different from one quarter to the next.

Because operating profit and net profit are moving in different directions, the choice of earnings base changes how the multiple reads.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Operating profit recovery

Operating profit rose for three straight quarters from Q1 to Q3 2026, and Q3 2026 operating profit of KRW 8.93 billion was up 35.2% year on year. The company said its operating margin also rose from the prior-year quarter. The turn after the lower 2025 margin is cited as the bull point.

Expanding consumables base

New installations of the main platforms reached 9,493 units in the first three quarters of 2026, up 26.7% year on year. Cartridge finished-product sales rose 24% to KRW 38 billion in Q3 2026 and 14.6% on a cumulative basis. The company explains that repeat cartridge purchases grow as installed devices accumulate.

Europe and domestic in-hospital testing

European sales rose 67% to KRW 14.1 billion in Q2 2026, lifting the region to about 30% of revenue. Domestic sales rose 44% in Q2 and 47% in the first half, supported by in-hospital testing demand ahead of the December outsourcing rule revision. Growth in advanced markets is cited as a partial offset to regional concentration.

09

Bear factors

Weak net profit

Profit attributable to controlling shareholders fell 13.1% to KRW 23.7 billion in 2025, and Q3 2026 profit of KRW 2.08 billion was down 73.3% year on year. It has declined for two quarters since the Q1 2026 peak. The bear case points to operating profit gains not reaching net profit.

Margin pressure and investment burden

The company cited expanded headcount and R&D as the reason for the lower operating margin, with staff rising from 321 at the end of 2019 to 618 at the end of 2025. If investment costs keep weighing on margins for longer, the pace of profit recovery could slow.

Targets and regional variables

Revenue of KRW 162.1 billion in 2025 fell short of the KRW 200 billion target set in a 2023 interview. Middle East and North Africa sales fell 6.2% in Q2 2026. The company said it faces difficulties in China from copycat products and political factors. The gap between targets and results is cited as a bear point.

10

Risk factors

Regional concentration and geopolitics

The Middle East and North Africa accounted for 26% of 2025 revenue, and sales there fell 6.2% in Q2 2026. The company said geopolitical uncertainty persists. Demand swings in one region can change quarterly revenue materially.

Dependence on regulatory change

Domestic in-hospital testing demand is linked to the December 2026 revision of the specimen testing outsourcing rules. Whether demand holds after implementation must be confirmed through future quarterly domestic sales. A weaker-than-expected effect would slow domestic growth.

Competition and investment burden

Chinese in-vitro diagnostics companies are widening their overseas reach on price competitiveness and government backing. The company's margin fell while it expanded headcount and R&D. Heavier competition combined with sustained investment could slow the margin recovery.

11

What to watch next

  1. December 2026

    Revision of the specimen testing outsourcing rules takes effect. The checkpoint is whether in-hospital demand sustains the 47% first-half domestic sales growth of 2026.

  2. End of March 2027

    Deadline for the 2026 annual report. It shows annual revenue growth and operating margin against 17.9% in 2025, plus the quarterly path of profit attributable to controlling shareholders.

  3. Early 2027

    Timing of the preliminary 2026 annual results. It is the point to compare actual growth with the 15% annual pace needed for the KRW 300 billion 2030 target.

  4. Early May 2027

    Preliminary Q1 2027 results. The Q1 2026 results were released on May 8. The checkpoints are whether profit attributable to controlling shareholders recovers from KRW 2.08 billion in Q3 2026 and whether the margin improvement holds.

12

Overall view

Boditech Med grew revenue from KRW 118.1 billion in 2022 to KRW 162.1 billion in 2025, and revenue growth has continued through Q3 2026. Operating profit rose to KRW 28.9 billion in 2025 and has increased for three straight quarters from Q1 to Q3 2026.

Profit attributable to controlling shareholders fell 13.1% in 2025 to KRW 23.7 billion and has declined for two quarters since Q1 2026, so the profit lines point in different directions.

Operating margin fell from 20.9% in 2022 to 17.9% in 2025, and in Q3 2026 operating profit growth outpaced revenue growth, a sign of recovery.

Growth drivers are cartridge sales tied to installed devices and demand from Europe and domestic in-hospital testing, while the Middle East, North Africa and China remain variables. The company's 2030 target is KRW 300 billion in revenue, and whether it is reached depends on sustained annual growth.

The price-to-book ratio is below 1x and debt is light. The next checkpoints are domestic sales after the December 2026 outsourcing rule revision, the operating margin in the 2026 annual report, and whether net profit recovers in Q1 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. getnews.co.kr
  2. medipharmhealth.co.kr
  3. monews.co.kr
  4. vegannews.co.kr
  5. rapportian.com
  6. paxetv.com
  7. m.news.nate.com
  8. msn.com
  9. medifonews.com
  10. sedaily.com
  11. hankyung.com
  12. ssl.pstatic.net
  13. pharm.edaily.co.kr
  14. news.nate.com
  15. rapportian.com
  16. sisajournal-e.com
  17. yakup.com
  18. news.mt.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis